Page 251 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
Careggi and 2Center for Innovation and Research in Myeloproliferative Neoplasms, Hematology Unit, Azienda Ospedaliera Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Correspondence:
A.M. VANNUCCHI - amvannucchi@unifi.it
https://doi.org/10.3324/haematol.2024.285934
Received: June 10, 2024. Accepted: August 27, 2024. Early view: September 5, 2024.
©2025 Ferrata Storti Foundation Published under a CC BY-NC license
Disclosures
AMV, MP, FM and GG received personal fees for advisory board services and/or lectures from AbbVie. The other authors have no conflicts of interest to report.
References
1. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377.
2. Bataller A, Bazinet A, DiNardo CD, et al. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024;8(4):927-935.
3. Döhner H, Pratz KW., DiNardo CD, et al. ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine. Blood. 2022;140(Supplement 1):1441-1444.
4. DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of
Contributions
GC, MP and AMV designed research, analyzed and interpreted data, and wrote the manuscript. FM, GG, BB, LF, FC, EQ, AP, JC, GR, FP, LS, CM, FIV and PG contributed data. GC, MP, FM and AMV performed research. All authors participated in interpreting the data. They all checked and approved the final version of the manuscript.
Funding
This work received financial support from Associazione Italiana per la Ricerca sul Cancro (AIRC) 5×1000 called “Metastatic disease: the key unmet need in oncology” to MYNERVA (MYeloid NEoplasms Research Venture AIRC), project #21267. It was also supported by a legacy from the Zottola family to UNIFI.
Data-sharing statement
The aggregated datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791-803.
5. Krüger K, Wichmann M, Gabdoulline R, et al. Predictors of response and outcome in patients with refractory/relapsed acute myeloid leukemia receiving venetoclax with non- intensive chemotherapy. Hemasphere. 2023;7(Suppl):e19815ef.
6. Apolito V, Arrigo G, Vasseur L, et al. Validation of SIE/SIES/ GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax. Br J Haematol. 2023;203(4):e98-e101.
Haematologica | 110 January 2025
243